摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-甲基-5-硝基苯甲酸 | 113882-33-0

中文名称
3-甲基-5-硝基苯甲酸
中文别名
——
英文名称
3-methyl-5-nitrobenzoic acid
英文别名
5-Methyl-3-nitrobenzoic acid
3-甲基-5-硝基苯甲酸化学式
CAS
113882-33-0
化学式
C8H7NO4
mdl
MFCD00129754
分子量
181.148
InChiKey
XAPRFOJQNGFJSZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    174℃
  • 沸点:
    355.8±30.0 °C(Predicted)
  • 密度:
    1.392±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    83.1
  • 氢给体数:
    1
  • 氢受体数:
    4

安全信息

  • 危险性防范说明:
    P261,P273,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335,H412

SDS

SDS:94dfe5c1f212d544f1c84efef0354fc2
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Methyl-5-nitrobenzoic acid
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Methyl-5-nitrobenzoic acid
CAS number: 113882-33-0

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H7NO4
Molecular weight: 181.1

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-甲基-5-硝基苯甲酸亚硝酸 、 iron(II) sulfate 作用下, 生成 3-羟基-5-甲基苯甲酸
    参考文献:
    名称:
    Mueller, Chemische Berichte, 1909, vol. 42, p. 433
    摘要:
    DOI:
  • 作为产物:
    描述:
    5-硝基间二甲苯吡啶potassium permanganate溶剂黄146 作用下, 以 二氯甲烷乙酸乙酯 为溶剂, 以40%的产率得到3-甲基-5-硝基苯甲酸
    参考文献:
    名称:
    Antibiotic compounds
    摘要:
    本发明涉及碳青霉烯类药物,并提供了如下式(I)的化合物:##STR1##或其药用可接受的盐或体内水解酯,其中:R.sup.1是1-羟乙基、1-氟乙基或羟甲基;R.sup.2是氢或C.sub.1-4烷基;R.sup.3是氢或C.sub.1-4烷基;R.sup.4和R.sup.5相同或不同,选自氢、卤素、氰基、C.sub.1-4烷基、硝基、羟基、羧基、C.sub.1-4烷氧基、C.sub.1-4烷氧羰基、氨基磺酰基、C.sub.1-4烷基氨基磺酰基、二C.sub.1-4烷基氨基磺酰基、氨甲酰基、C.sub.1-4烷基氨甲酰基、二C.sub.1-4烷基氨甲酰基、三氟甲基、磺酸、氨基、C.sub.1-4烷基氨基、二C.sub.1-4烷基氨基、C.sub.1-4烷酰胺基、C.sub.1-4烷酰(N-C.sub.1-4烷基)氨基、C.sub.1-4烷磺酰胺基和C.sub.1-4烷基S(O).sub.n --其中n为零、一或二:但条件是在--NR.sup.2--的邻位没有羟基或羧基取代基。它们的制备方法,制备中间体,作为治疗剂的用途以及含有它们的药物组合物。
    公开号:
    US05478820A1
点击查看最新优质反应信息

文献信息

  • ISOTHIOUREA DERIVATIVES OR ISOUREA DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY
    申请人:Tamura Yuusuke
    公开号:US20120015961A1
    公开(公告)日:2012-01-19
    The present invention provides, for example, a compound of the following formula (I): wherein R 1 is substituted amino and the like, R 2 is halogen and the like, R 3 is substituted or unsubstituted lower alkyl and the like, R A and R B are each independently hydrogen, substituted or unsubstituted lower alkyl and the like, R C and R D are each independently hydrogen, substituted or unsubstituted lower alkyl, or R C and R D together with the carbon atom to which they are attached may form a substituted or unsubstituted carbocycle, and ring A is a carbocycle or a heterocycle, its pharmaceutically acceptable salt, or a solvate thereof as a therapeutic agent for diseases induced by production, secretion and/or deposition of amyloid-βproteins.
    本发明提供了以下式(I)的化合物,例如: 其中R 1 是取代氨基等, R 2 是卤素等, R 3 是取代或未取代的较低烷基等, R A 和R B 各自独立地是氢、取代或未取代的较低烷基等, R C 和R D 各自独立地是氢、取代或未取代的较低烷基,或R C 和R D 与它们连接的碳原子一起可以形成取代或未取代的碳环,以及 环A是碳环或杂环, 其药学上可接受的盐,或其溶剂合物作为由淀粉样蛋白β的产生、分泌和/或沉积引起的疾病的治疗剂。
  • 激酶抑制剂
    申请人:曼彻斯特大学
    公开号:CN112119077A
    公开(公告)日:2020-12-22
    本发明涉及某些4‑(取代的苯胺)‑2‑(取代的哌啶‑1‑基)嘧啶‑5‑甲酰胺化合物,其可用于治疗或预防通过CaMK1同种型的信号传导介导的疾病或医学病况。例如,此类化合物及其盐可用于治疗或预防多种不同的癌症、代谢性疾病(包括2型糖尿病)和/或免疫介导的疾病。
  • BENZAMIDE FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS
    申请人:Priestley Eldon Scott
    公开号:US20100227894A1
    公开(公告)日:2010-09-09
    The present invention provides novel benzamide derivatives of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate, or prodrug thereof, wherein the variables A, W, Y, Z, R 8 , and R 9 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.
    本发明提供了式(I)的新型苯甲酰胺衍生物:或其立体异构体、互变异构体、药学上可接受的盐、溶剂合物或前药,其中变量A、W、Y、Z、R8和R9如本文所定义。这些化合物是选择性因子VIIa的抑制剂,可用作药物。
  • BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS
    申请人:PRELUDE THERAPEUTICS INCORPORATED
    公开号:US20210346405A1
    公开(公告)日:2021-11-11
    The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.
    该披露涉及部分BCL-2抑制剂,包括含有它们的药物组合物,以及它们的使用和制备方法。
  • 3-ACETYLENYL-PYRAZOLE-PYRIMIDINE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND USES THEREOF
    申请人:Si Chuan University
    公开号:US20170305920A1
    公开(公告)日:2017-10-26
    The present invention relates to the field of chemical and medicine, more particularly, 3-ethynylpyrazolopyrimidine derivatives and their preparation methods and uses. The invention provides a 3-ethynylpyrazolopyrimidine derivative, and the structure is shown in formula I. The present invention also provides preparation methods and use of 3-ethynylpyrazolopyrimidine derivatives, comprising the compounds and derivatives, and their pharmaceutical compositions for the use of the treatment and prevention of tumors.
    本发明涉及化学和药物领域,更具体地涉及3-乙炔吡唑吡嘧啶衍生物及其制备方法和用途。该发明提供了一种3-乙炔吡唑吡嘧啶衍生物,其结构如公式I所示。本发明还提供了3-乙炔吡唑吡嘧啶衍生物的制备方法和用途,包括该化合物和衍生物,以及它们的药物组合物,用于治疗和预防肿瘤。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐